About
Consulting
Asset Prioritization
Business Development
Competitive Intelligence
Licensing Services
Merger and Acquisitions
Partner Identification
Competitive Benchmarking
Portfolio Management
R&D Analysis
Pipeline Assessment
Market Assessment
Regulatory Analysis
Due Diligence
Capabilities
Medical Devices
Market Research
Subscription
Competitive Intelligence
Business Consulting
Report Store
Insights
Blog
Events
Case-Study
COVID-19
Infographics
Press Release
Newsletter/Whitepaper
Contact
Cart
0
EUROPEAN SOCIETY
FOR MEDICAL ONCOLOGY
(ESMO) 2020
Home
ESMO Conference 2020
All
Filters:
Targets/Technology
Immune Checkpoint Inhibitors
Classes showing abundant growth (PARP inhibitors, CDK4/6 inhibitors)
Others
Cell therapies (CAR-T/TCR/TCR2)
Promising new classes (viz.AKT inhibitors; BiTE)
multiTKI
Bispecific Antibodies
BCMA-ADC
Promising next gen Immunotherapies (LAG-3/ICOS/TIM-3)
+ SHOW MORE
Indications
Others
Breast Cancer( HER2-ve; HER2+ve, TNBC)
Melanoma
Lung Cancer (NSCLC; SCLC)
Renal Cell Carcinoma (RCC)
Urothelial Carcinoma
Head and Neck Cancer
Colorectal Cancer
Glioblstoma; High Grade Glioma
Merkel cell carcinoma
Diffused Large B-Cell Lymphoma (DLBCL)
Prostate Cancer (HSPC, CRPC)
Ovarian Cancer
Cutaneous squamous cell carcinoma (SCC)
Cervical Cancer
Gastrointestinal Cancer
Gastroesophageal adenocarcinoma
Adenoid Cystic Carcinoma
Pancreatic Cancer
Thyroid Cancer
Tenosynovial Giant Cell Tumor
Cholangiocarcinoma
Esophageal Cancer
Solid Tumors
Intrahepatic Cholangiocarcinoma
Desmoid Tumor
+ SHOW MORE
-- End of the Page --
